Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

By Bruno Dubois, H. Feldman, C. Jacova, Steven DeKosky, P. Barberger‐Gateau, Jeffrey L. Cummings, A. Delacourte, D. Galasko, S. Gauthier, G. Jicha and 9 more. Lancet Neurology, 2007

4,401 citations recorded by the source corpus.

Subfields: Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/e0a1535dd767e4f50c95ab2c8e0f6001b74b34f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Genetics of Alzheimer's Disease (2013, neutral): “Hindawi Publishing Corporation BioMed Research International Volume 2013, Article ID 254954, 13 pages http://dx.doi.org/10.1155/2013/254954”
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018, positive): “While differences remain, IWG 2016 and the NIA research framework are aligned on the key issue that the combination of an abnormal Ab and tau biomarker constitutes AD regardless of cognitive symptoms, and thus AD is a biologically defined entity throughout its continuum.”
Classifying neurocognitive disorders: the DSM-5 approach (2014, methodology): “Other biomarkers for AD diagnosis, 23 such as levels of amyloid‑β 42 and phosphorylated tau in cerebrospinal fluid, are in the research arena and not yet ready for the clinic.”
Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests (2011, background): “Recently, it has become possible to identify the traces, or biomarkers, of Alzheimer ’ s disease in patients with MCI, by the use of Magnetic Resonance Imaging (MRI) volumetric studies, neurochemical analysis of the cerebrospinal fluid, and Positron Emission Tomography (PET) scan [5].”
Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging (2009, positive): “In the past years, the early clinical signs of AD have been extensively investigated, leading to the concept of amnestic Mild Cognitive Impairment (MCI) (Dubois and Albert, 2004; Dubois et al., 2007; Petersen, 2004; Petersen et al., 2001; Winblad et al., 2004).”
Introduction to Revised Criteria for the Diagnosis of Alzheimer’s Disease: National Institute on Aging and the Alzheimer Association Workgroups (2011, background): “[18] Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P,”
A multi-task learning formulation for predicting disease progression (2011, background): “ing disease progression include neuroimages such as magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), and baseline clinical assessments [12].”
Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms (2008, methodology): “Instead of the traditional two-step approach consisting of first identifying dementia syndrome and then specifying its causative agents, new empirical criteria aim at defining the clinical, biochemical, and metabolic markers of AD before the criteria of dementia are clinically fulfilled.(2) In that ”
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. (2012, background): “Evaluation of the optimal combinations of biomarkers for the identification of prodromal AD in patients with MCI, and of their interaction, needs to be performed in large MCI cohorts with extensive follow-up.(4,7) Note that the incidence of AD dementia in patients with MCI with normal A 42:P-tau rat”